IDWEEK 2016 – Adult Infectious Diseases

The authors gathered clinical and demographic data from the University of Kentucky Center for Clinical and Translational Science Enterprise Data Trust, for adults who received TZP+VAN or CFP+VAN for ≥48 hours in the ICU.

With international travel, “any outbreak, anywhere in the world can be a threat, everywhere.” That’s the reality of an increasingly connected world, said Malik Peiris, PhD, of the School of Public Health at the HKU-Pasteur Research Center, The University of Hong Kong, Pokfulam, Hong Kong, at IDWeek 2016.

The overall risk of hepatic decompensation in patients treated with the paritaprevir/ritonavir, ombitasvir, dasabuvir (PrOD) regimen during and up to 12 weeks after completion of treatment was low, Adeel A. Butt, MD, MS, of the VA Pittsburgh Healthcare System, Pittsburgh, PA, told IDWeek 2016 attendees.

Minocycline “may be a good choice” for infections caused by Stenotrophomonas maltophilia, “an inherently resistant organism with limited treatment options,” concluded authors of a retrospective study presented at IDWeek.

Overall sustained virologic response (SVR) rate for ledipasvir/sofosbuvir in hepatitis C virus (HCV)/HIV co-infected patients in real world settings was 95.2%.

Relebactam (MK-7655) restored imipenem activity against many respiratory tract infection isolates from the US and Canada, researchers reported at IDWeek 2016.

For patients with hepatitis C virus (HCV) infection genotype (GT) 1-6, treatment with sofosbuvir/velpatasvir plus voxilaprevir (GS-9857) once daily was safe, well tolerated, and highly effective in treatment-naive and treatment-experienced patients, reported Ronald Nahass, MD, FIDSA, FSHEA, from ID Care, Inc., Hillsborough, NJ, at IDWeek 2016.

An age- and gender-based pooled analysis presented at IDWeek 2016 showed that delafloxacin had comparable outcomes to vancomycin at 48-72 hours for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

A total of 2,538 patients taking piperacillin/tazobactam and 1,134 patients taking levofloxacin were included in the analysis.

Trimethoprim-sulfamethoxazole (TMP-SMX) or clindamycin treatment following small abscess incision and drainage (I&D) improves outcomes.